仙琚製藥(002332.SZ):收到炔雌醇環丙孕酮片一致性評價受理通知書
格隆匯5月7日丨仙琚製藥(002332.SZ)公佈,公司於近日收到國家藥品監督管理局下發的炔雌醇環丙孕酮片一致性評價受理通知書。
本次申報的炔雌醇環丙孕酮片每片含醋酸環丙孕酮2mg和炔雌醇0.035mg,主要適應症爲可用於治療婦女雄激素依賴性疾病(包括多囊卵巢綜合徵患者的高雄性激素表現),例如痤瘡,特別是明顯的類型,和伴有皮脂溢、炎症或形成結節的痤瘡(丘疹膿泡性痤瘡、結節囊腫性痤瘡)、婦女雄激素性脫髮、輕型多毛症、以及具有上述疾病婦女的口服避孕。公司炔雌醇環丙孕酮片已批準上市的規格爲每片含醋酸環丙孕酮2mg和炔雌醇0.035mg,批準文號分別爲:國藥準字H20065479,目前產品執行標準爲WS1-XG-021-2011。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.